Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 2/20 | 0.31 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.31 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KHK | P50053 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731400 | 0.94 | PDE4D (0.34) | MAP3K12LRRK2ALDH1A1HPGDKHK | |
| SCHEMBL4731388 | 0.93 | — | — | |
| SCHEMBL14221785 | 0.86 | PIK3CA (0.34) | MAP3K12PIK3CAPRKDC | |
| SCHEMBL4733136 | 0.83 | KDM4E (0.33) | ALDH1A1HPGD | |
| SCHEMBL4919594 | 0.82 | — | — | |
| SCHEMBL4784718 | 0.82 | KDM1A (0.30) | — | |
| SCHEMBL4781015 | 0.80 | L3MBTL1 (0.35) | ALDH1A1 | |
| SCHEMBL4110176 | 0.74 | KDM4E (0.34) | ALDH1A1 | |
| SCHEMBL4731703 | 0.73 | — | — | |
| SCHEMBL4109260 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | claimed |
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | disclosed |
| WO-2008047224-A1 | PYRAZOLYL-4-OXY-BENZONITRILE DERIVATIVES USEFUL IN TREATING ENDOMETRIOSIS | PFIZER LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047224-A1 | PYRAZOLYL-4-OXY-BENZONITRILE DERIVATIVES USEFUL IN TREATING ENDOMETRIOSIS | PFIZER LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096950-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096950-A1 | Compounds Useful In Therapy | CYP19A1, LPXN, HSD17B11 | MAP3K12 2625/4885FLT3 4648/4885MAP3K1 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.